title: Pyrazolopyridines as inhibitors of the kinase LRRK2: a patent evaluation (WO2011141756).
abstract: Scientific evaluation of a patent aiming for the development of pyrazolopyridine derivatives as LRRK2 kinase inhibitors, a potential therapeutic target for combating Parkinson's disease.
authors.affiliation: Dana-Farber Cancer Institute, Harvard Medical School, Department of Biological Chemistry & Molecular Pharmacology, 250 Longwood Ave, SGM 628, Boston, MA 02115, USA.
authors.forename: Xianming
authors.initials: X
authors.lastname: Deng
authors.forename: Nathanael
authors.initials: N
authors.lastname: S Gray
mesh_terms: D000818:Animals; D000978:Antiparkinson Agents / Q000737:chemistry / Q000494:pharmacology*; D015195:Drug Design; D006801:Humans; D000071158:Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; D015394:Molecular Structure; D010330:Patents as Topic; D047428:Protein Kinase Inhibitors / Q000737:chemistry / Q000494:pharmacology*; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D011720:Pyrazoles / Q000737:chemistry / Q000494:pharmacology*; D011725:Pyridines / Q000737:chemistry / Q000494:pharmacology*; D013329:Structure-Activity Relationship
chemical_list: D000978:Antiparkinson Agents; D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; D011725:Pyridines; C118531:pyrazolopyridine; C495280:LRRK2 protein, human; D000071158:Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; D017346:Protein Serine-Threonine Kinases